Business Wire

Amazfit Ambassador Ruth Croft Claims Victory at the 2025 UTMB

5.9.2025 11:00:00 CEST | Business Wire | Press Release

Share

Amazfit, a leading global smart wearable brand by Zepp Health (NYSE: ZEPP), is proud to celebrate Ruth Croft’s achievement at the 2025 UTMB, earning first place and completing the UTMB with a time of 22 hours, 56 minutes, and 23 seconds. She is the first female to win OCC, CCC, and now UTMB.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250905921121/en/

Amazfit is proud to celebrate Ruth Croft’s achievement at the 2025 UTMB, earning first place and completing the UTMB with a time of 22 hours, 56 minutes, and 23 seconds. She is the first female to win OCC, CCC, and now UTMB.

UTMB is recognized as the pinnacle of trail running, drawing the sport’s most elite athletes and thousands of passionate fans to the Mont-Blanc region each year. Known as one of the most demanding races in the world, the UTMB challenges competitors with grueling climbs, extreme weather conditions, and 9,900m elevation gain.

Ruth Croft credited the newly launched Amazfit T-Rex 3 Pro with supporting her performance during the race. Tested by elite athletes ahead of its release, the watch’s endurance-focused design, advanced GPS technology, and long battery life helped her monitor pace, heart rate, and performance readiness throughout the extraordinary journey.

In addition, Ruth used the Amazfit Helio Arm Band and Helio Ring, paired to her watch, to track real-time heart rate during the race. Leading up to the event, she used the Amazfit Helio Strap to monitor her recovery, resting heart rate, and sleep.

“I couldn’t have asked for a better day. I was able to manage the cold weather conditions through the evening, and then get back into race mode once day broke. It was made even better getting to share this lap around Mont Blanc with my family and friends.”

— Ruth Croft, Amazfit Ambassador and 2025 UTMB Champion

Amazfit athletes made their mark across the 2025 UTMBraces. American ultra runner Rod Farvard also relied on the Amazfit T-Rex 3 Pro, paired with the Helio Strap and Helio Ring, to secure the ninth place on his birthday in 21 hours, 18 minutes, and 24 seconds. Rising talent Rosa Lara Feliu used the Amazfit T-Rex 3 Pro and Helio Strap as well to push her way to a strong seventh in the OCC. Together, their performances reflect Amazfit’s support for athletes on the world’s most iconic trails.

Amazfit is committed to empowering athletes with the most advanced outdoor wearable technology. During UTMB week in Chamonix, Amazfit previewed the T-Rex 3 Pro ahead of its official launch and showcased the Helio Strap through athlete meet-and-greets, community activations, and hands-on product demonstrations.

This achievement adds to Amazfit’s growing investment in performance sport, all part of a long-term strategy to create products and programs built for athletes, by athletes.

About Amazfit

Amazfit, a leading global smart wearable brand focused on health and fitness, is part of Zepp Health (NYSE: ZEPP), a health technology company with its principal office based in Gorinchem, the Netherlands. Zepp Health operates as a distributed organization, with team members and offices across the Americas, Europe, Asia, and other global markets.

Offering a wide selection of smartwatches and bands, Amazfit's brand tagline, “Discover Amazing,” encourages individuals to break barriers, exceed expectations, and find joy in every moment. Amazfit is powered by Zepp Health’s proprietary health management platform, which delivers cloud-based, 24/7 actionable insights and guidance to help users achieve their wellness goals.

Known for outstanding craftsmanship, Amazfit smartwatches have won numerous design awards, including the iF Design Award and the Red Dot Design Award. Launched in 2015, Amazfit is embraced by millions of users, with products available in over 90 countries across the Americas, EMEA, and APAC regions. For more information, visit www.amazfit.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250905921121/en/

Contacts

Media Contacts
Max Borges Agency for Amazfit
amazfit@maxborgesagency.com

Mary Thompson Woodbury
Head of PR, Amazfit North America
Mary.woodbury@zepp.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye